EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phosphatidylinositol 4-Kinase IIIβ: A Therapeutic Target for Contractile Dysfunction in Hypertrophic Cardiomyocytes

Myrthe M A Willemars iD, Aomin Sun iD, Shujin Wang, Ozlenen Simsek Papur, Agnieszka Brouns-Strzelecka, Rick van Leeuwen, Sabina J V Vanherle, Dimitrios Kapsokalyvas iD, Jan F C Glatz iD, Dietbert Neumann iD, Miranda Nabben iD, Joost J F P Luiken

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Myrthe M A Willemars und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics & Cell Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Cardiomegaly, Myocardial Contraction, Phosphotransferases (Alcohol Group Acceptor). Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Heart foundation, China Scholarship Council, TUBITAK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac hypertrophy is an important risk factor for heart failure and is often accompanied by contractile dysfunction. While hypertrophic growth contributes to disease progression, the underlying molecular mechanisms remain incompletely understood. A proposed contributor is a metabolic shift toward glucose uptake, suggesting that kinases regulating this process, such as protein kinase D1 (PKD1) and downstream target phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ), might be effective targets to mitigate cardiac hypertrophy-induced contractile dysfunction. We investigated whether PI4KIIIβ inhibition downregulates enhanced glucose uptake in hypertrophic cardiomyocytes and thereby treats cardiac hypertrophy-induced contractile dysfunction. Hypertrophy was induced in cultured adult rat cardiomyocytes and human stem cell-derived cardiomyocytes using either phenylephrine (PE) or adenoviral PKD1 overexpression. PE-induced hypertrophy was associated with increased mRNA expression of BNP, activation of hypertrophic signaling, morphological alterations, enhanced protein synthesis and glucose uptake, and impaired contractile function. Treatment with the PI4KIIIβ inhibitor MI14 prevented and reversed PE-stimulated glucose uptake and contractile dysfunction, while hypertrophic signaling, cell size, and protein synthesis remained unaffected. Similar effects on glucose uptake were observed in the PKD1 overexpression model. These findings suggest that targeting myocardial substrate metabolism via the PI4KIIIβ pathway, rather than hypertrophic growth itself, could be a promising strategy to treat hypertrophy-induced contractile dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacCardiomegalyMyocardial ContractionPhosphotransferases (Alcohol Group Acceptor)1-Phosphatidylinositol 4-KinaseAnimalsRatsHumansGlucosePhenylephrineCells, CulturedSignal Transduction

Stichwörter der Autor:innen

cardiac hypertrophycardiac metabolismcontractile dysfunctionheart failurephosphatidylinositol 4-kinase IIIβ

Substanzen

GlucosePhenylephrinePhosphotransferases (Alcohol Group Acceptor)1-Phosphatidylinositol 4-Kinase

Autor:innen und Institutionen

  • Department of Genetics & Cell Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • Cardiovascular Research Institute Maastricht (CARIM), 6229 ER Maastricht, The Netherlands.
  • Department of Physiology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6229 ER Maastricht, The Netherlands.
  • Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
  • Key Laboratory of Cell Proliferation and Regulation Biology, Ministry of Education, College of Life Sciences, Beijing Normal University, Beijing 100875, China.
  • Institute of Life Sciences, School of Basic Medicine, Chongqing Medical University, Chongqing 400016, China.

ORCID-Profile: Myrthe M A Willemars, Aomin Sun, Dimitrios Kapsokalyvas, Jan F C Glatz, Dietbert Neumann, Miranda Nabben

Förderung

  • Dutch Heart foundation
  • China Scholarship Council
  • TUBITAK

Zitieren

APA

Willemars, M. M. A., Sun, A., Wang, S., Simsek Papur, O., Brouns-Strzelecka, A., van Leeuwen, R., Vanherle, S. J. V., Kapsokalyvas, D., Glatz, J. F. C., Neumann, D., Nabben, M., & Luiken, J. J. F. P. (2026). Phosphatidylinositol 4-Kinase IIIβ: A Therapeutic Target for Contractile Dysfunction in Hypertrophic Cardiomyocytes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020595

Vancouver

Willemars MMA, Sun A, Wang S, Simsek Papur O, Brouns-Strzelecka A, van Leeuwen R, et al. Phosphatidylinositol 4-Kinase IIIβ: A Therapeutic Target for Contractile Dysfunction in Hypertrophic Cardiomyocytes. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020595

BibTeX
@article{Willemars2026,
  author = {Willemars, Myrthe M A and Sun, Aomin and Wang, Shujin and Simsek Papur, Ozlenen and Brouns-Strzelecka, Agnieszka and van Leeuwen, Rick and Vanherle, Sabina J V and Kapsokalyvas, Dimitrios and Glatz, Jan F C and Neumann, Dietbert and Nabben, Miranda and Luiken, Joost J F P},
  title = {Phosphatidylinositol 4-Kinase IIIβ: A Therapeutic Target for Contractile Dysfunction in Hypertrophic Cardiomyocytes},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020595}
}
Kostenlos starten →